{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:22:17Z","timestamp":1775323337221,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015660","name":"UCB Research Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.yebeh.2022.108985","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T09:38:08Z","timestamp":1669369088000},"page":"108985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["BRIVEST: A \u2018real-world\u2019 observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam"],"prefix":"10.1016","volume":"138","author":[{"given":"Sophie","family":"Naddell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Cavill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7503-9896","authenticated-orcid":false,"given":"Paul","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9019-4974","authenticated-orcid":false,"given":"Katarzyna","family":"Sieradzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108985_b0005","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.108985_b0010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.108985_b0015","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.2147\/NDT.S143548","article-title":"Brivaracetam in the treatment of epilepsy: a review of clinical trial data","volume":"15","author":"Feyissa","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2022.108985_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/ane.12703","article-title":"A review of medication adherence in people with epilepsy","volume":"135","author":"Malek","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108985_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107897","article-title":"Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial","volume":"118","author":"Toledo","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0030","unstructured":"UCB Pharma, Malvern, Australia. Briviact (brivaracetam) Film-coated Tablets and Oral Solution: Consumer Medical Information 2019. Retrieved from https:\/\/www.nps.org.au\/assets\/medicines\/a5b5b105-2a69-4119-add3-a79f00b3a615-reduced.pdf."},{"key":"10.1016\/j.yebeh.2022.108985_b0035","unstructured":"UCB Pharma, Brussels, Belgium. Briviact\u00ae Summary of product characteristics 2022. Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf."},{"key":"10.1016\/j.yebeh.2022.108985_b0040","unstructured":"UCB Inc, Smyrna, GA, US. Briviact\u00ae US. Highlights of Prescribing Information 2021. Retrieved from https:\/\/www.briviact.com\/briviact-PI.pdf."},{"key":"10.1016\/j.yebeh.2022.108985_b0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","article-title":"Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial","volume":"75","author":"French","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108985_b0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","volume":"54","author":"van Paesschen","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0070","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0075","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol: Adv Appl"},{"key":"10.1016\/j.yebeh.2022.108985_b0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/jm030913e","article-title":"Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity","volume":"47","author":"Kenda","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2022.108985_b0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","article-title":"Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond","volume":"30","author":"L\u00f6scher","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108985_b0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1528-1167.2010.02869.x","article-title":"Targeting SV2A for Discovery of Antiepileptic Drugs","volume":"51","author":"Kaminski","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111462","article-title":"Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein","volume":"138","author":"Okada","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108985_b0100","doi-asserted-by":"crossref","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Nat Acad Sci U S A 2004;101:9861. https:\/\/doi.org\/10.1073\/PNAS.0308208101.","DOI":"10.1073\/pnas.0308208101"},{"key":"10.1016\/j.yebeh.2022.108985_b0105","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (UCB 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108985_b0110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/DDDT.S103468","article-title":"New developments in the management of partial-onset epilepsy: role of brivaracetam","volume":"11","author":"Coppola","year":"2017","journal-title":"Drug Design, Dev Ther"},{"key":"10.1016\/j.yebeh.2022.108985_b0115","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/epi.14701","article-title":"A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers","volume":"60","author":"Finnema","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108985_b0125","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/17460441.2017.1366985","article-title":"The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy","volume":"12","author":"Russo","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.yebeh.2022.108985_b0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eplepsyres.2009.09.024","article-title":"Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture","volume":"88","author":"Zona","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0135","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1111\/epi.13890","article-title":"Brivaracetam does not modulate ionotropic channels activated by glutamate, \u03b3-aminobutyric acid, and glycine in hippocampal neurons","volume":"58","author":"Niespodziany","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0140","first-page":"1","article-title":"\u0391 Multicenter Retrospective Study Evaluating Brivaracetam in the Treatment of Epilepsies in Clinical Practice","volume":"14","author":"Stefanatou","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.yebeh.2022.108985_b0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1756285616665564","article-title":"Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base","volume":"9","author":"Brandt","year":"2016","journal-title":"Ther Adv Neurol Disorders"},{"key":"10.1016\/j.yebeh.2022.108985_b0150","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","article-title":"Brivaracetam add-on for refractory focal epilepsy","volume":"86","author":"Lattanzi","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108985_b0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108985_b0160","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/epi.13416","article-title":"Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures","volume":"57","author":"Toledo","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eplepsyres.2016.09.003","article-title":"Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies","volume":"127","author":"Moseley","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/epi.16484","article-title":"Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial","volume":"61","author":"O\u2019Brien","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106526","article-title":"Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial","volume":"170","author":"Ben-Menachem","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE\u2013A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108985_b0185","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106967","article-title":"Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation","volume":"106","author":"Adewusi","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0195","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/epi.16769","article-title":"Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis","volume":"62","author":"Lattanzi","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0200","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40263-021-00856-3","article-title":"Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108985_b0205","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1111\/epi.17087","article-title":"Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","article-title":"Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey","volume":"48","author":"Steinhoff","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108985_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106505","article-title":"Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability","volume":"99","author":"Foo","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107746","article-title":"Adjunctive brivaracetam \u2013 A prospective audit of outcomes from an epilepsy clinic","volume":"116","author":"Stephen","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0230","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","article-title":"Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis","volume":"61","author":"Hirsch","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108985_b0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2018.11.032","article-title":"Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities","volume":"90","author":"Theochari","year":"2019","journal-title":"Epilepsy Behav: E&B"},{"key":"10.1016\/j.yebeh.2022.108985_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eplepsyres.2017.02.007","article-title":"Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study","volume":"131","author":"Asadi-Pooya","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0250","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1528-1167.2012.03500.x","article-title":"Epilepsy and psychiatric comorbidity: A nationally representative population-based study","volume":"53","author":"Rai","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0255","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijerph16081451","article-title":"A Meta-Analysis of the Rates of Suicide Ideation, Attempts and Deaths in People with Epilepsy","volume":"16","author":"Abraham","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.yebeh.2022.108985_b0260","doi-asserted-by":"crossref","unstructured":"Mula M. Epilepsy and Psychiatric Comorbidities: Drug Selection. Curr Treat Opt Neurol 2017;19(12):1\u201311. https:\/\/doi.org\/10.1007\/S11940-017-0483-0.","DOI":"10.1007\/s11940-017-0483-0"},{"key":"10.1016\/j.yebeh.2022.108985_b0265","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2019.04.021","article-title":"Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study","volume":"69","author":"Toledo","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108985_b0270","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.seizure.2006.04.002","article-title":"Epilepsy in adults with intellectual disabilities: Prevalence, associations and service implications","volume":"15","author":"McGrother","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108985_b0275","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ane.12943","article-title":"Behavioural changes in patients with intellectual disability treated with brivaracetam","volume":"138","author":"Andres","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108985_b0280","doi-asserted-by":"crossref","unstructured":"Gillis RME, Wammes-van der Heijden EA, Schelhaas HJ, Tan IY, Festen DAM, Majoie MHJM. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy. Acta Neurol Belgica 2020;121(3):677\u201384. https:\/\/doi.org\/10.1007\/S13760-020-01324-3.","DOI":"10.1007\/s13760-020-01324-3"},{"key":"10.1016\/j.yebeh.2022.108985_b0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14581\/jer.19003","article-title":"Epilepsy in the Elderly: Treatment and Consideration of Comorbid Diseases","volume":"9","author":"Lee","year":"2019","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0290","doi-asserted-by":"crossref","first-page":"e030746","DOI":"10.1136\/bmjopen-2019-030746","article-title":"First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study","volume":"9","author":"Menzler","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2022.108985_b0295","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2011.03018.x","article-title":"Common data elements in epilepsy research: Development and implementation of the NINDS epilepsy CDE project","volume":"52","author":"Loring","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0300","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1528-1167.2005.49704.x","article-title":"Screening for major depression in epilepsy with common self-report depression inventories","volume":"46","author":"Jones","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yebeh.2014.03.003","article-title":"Screening for depression in people with epilepsy: Comparative study among Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), Hospital Anxiety and Depression Scale Depression Subscale (HADS-D), and Beck Depression Inventory (BDI)","volume":"34","author":"de Oliveira","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","article-title":"Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory","volume":"39","author":"Cramer","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0315","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0320","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0325","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108985_b0330","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.yebeh.2019.03.003","article-title":"Brief Communication Evolving dynamic networks: An underlying mechanism of drug resistance in epilepsy?","volume":"94","author":"Woldman","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106694","article-title":"Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis","volume":"176","author":"Moseley","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3988\/jcn.2014.10.3.175","article-title":"Depression and anxiety in people with epilepsy","volume":"10","author":"Kwon","year":"2014","journal-title":"J Clin Neurol (Korea)"},{"key":"10.1016\/j.yebeh.2022.108985_b0345","first-page":"1109","article-title":"Research progress on the mechanism of aggressive behavior induced by antiepileptic drugs","volume":"22","author":"Hou","year":"2020","journal-title":"J Chinese Phys"},{"key":"10.1016\/j.yebeh.2022.108985_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106369","article-title":"Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial","volume":"167","author":"Klein","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0355","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2018.00569","article-title":"Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany","volume":"9","author":"Willems","year":"2018","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108985_b0360","first-page":"95","article-title":"Brivaracetam in treating epileptic encephalopathy and refractory focal epilepsies in patients under 14 years of age","volume":"15","author":"Russo","year":"2021","journal-title":"Iran J Child Neurol Fall"},{"key":"10.1016\/j.yebeh.2022.108985_b0365","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eplepsyres.2016.08.018","article-title":"Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies","volume":"127","author":"Brodie","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108985_b0370","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.yebeh.2018.10.018","article-title":"Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents","volume":"89","author":"Schubert-Bast","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108985_b0375","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12098-021-03697-6","article-title":"Effectiveness and Safety of Brivaracetam in Children","volume":"88","author":"Gowda","year":"2021","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108985_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106541","article-title":"Treatment with brivaracetam in children \u2013 The experience of a pediatric epilepsy center","volume":"101","author":"Nissenkorn","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108985_b0385","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1192\/bjp.2020.212","article-title":"Mental health and well-being during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study","volume":"218","author":"O\u2019Connor","year":"2021","journal-title":"British J Psychiatr"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108985_b0390","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/PSY.0000000000000871","article-title":"Mental Health during COVID-19 Lockdown in the United Kingdom","volume":"83","author":"Pieh","year":"2021","journal-title":"Psychosom Med"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:50:26Z","timestamp":1761504626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022004346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":78,"alternative-id":["S1525505022004346"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108985","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRIVEST: A \u2018real-world\u2019 observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108985"}}